Abstract
Rationale: PNI is a prognostic factor in lung cancer pts. However, its role in oncogene addicted setting is limited and based on small size trials conducted mainly in Asian and in EGFR-mutated pts. Here we reported our preliminary Results of an Italian single institution experience conduced in oncogene addicted aNSCLC pts treated with tyrosine kinase inhibitors (TKIs).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
